Navigation Links
Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea

s of $3.2 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements regarding the potential for commercializing tolevamer in the future, when data from this Phase 3 study of tolevamer will be presented and when the results of the second Phase 3 study of tolevamer will be available. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the actual safety and efficacy of tolevamer; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of tolevamer for CDAD and the timing of such discussions; additional analysis of the data from the first Phase 3 study; the results of the second Phase 3 study and whether such results are consistent with this data; the timing of the second Phase 3 study; and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the qu
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genzyme Announces Results of Clinical Trial of Hylastan
2. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Inc. (DCI), announced that the company has received ... its New Drug Application (NDA) for PERTZYE™, indicated ... due to cystic fibrosis (CF) or other conditions.  ... enzyme product containing bicarbonate-buffered enteric-coated microspheres and is ...
... Inc. today announced that company personnel will deliver a ... Week (DDW) annual meeting at 9 a.m. PDT on ... Center in San Diego, California. DDW attracts thousands of ... share the latest research in gastrointestinal health topics, for ...
Cached Medicine Technology:Digestive Care, Inc. Announces FDA Approval of PERTZYE™ (pancrelipase) Delayed-Release Capsules 2Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease 2
(Date:8/31/2015)... ... 31, 2015 , ... Intellitec Solutions announced they have reached a record for ... new staff member in 2015. With the potential for more hiring occurring before the ... Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and has hired new support staff ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/30/2015)... California (PRWEB) , ... August 31, 2015 , ... Avid ... Morrison and the Doors Shrine Auditorium concert posters. This hand colored artwork is one ... and 23 in Los Angles. Hawley states, "When the doors played the Shrine, ...
(Date:8/30/2015)... ... 2015 , ... ChopChop Kids, the nonprofit publisher of the ... two new officers to serve on the organization’s Board of Directors in accordance ... kids to cook real food with their families and help continue to drive ...
(Date:8/30/2015)... ... ... Scientists in France say asbestos exposure may put workers at higher risk ... just posted an article on the new research. Click here to read it ... 2,024 French asbestos plant workers from 1978 to 2009. In addition to mesothelioma, the ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2
... in as the 5th Chair on "The Doctors", LOS ... be the guest co-host on the number one new syndicated,talk ... (check local,listings, http://www.thedoctorstv.com )., Best known from the ... York Times Bestselling Author for his book, Billion Dollar Smile,sits ...
... fatal parasite; first vaccines delivered following major funding award. ... that could eradicate a fatal form of brain disease ... soon be commercially available thanks to multi-million dollar funding. ... million tapeworm infections and 50,000 deaths from brain disease ...
... Abbott (NYSE: ABT ),will present at the 17th ... Thomas C. Freyman, executive vice president, finance,and chief financial ... 5,p.m. CST., A live audio webcast of the ... at http://www.abbottinvestor.com . An,archived edition of the presentation ...
... for stroke ... treatment, ... a team,of stroke experts from the West Virginia University Health Sciences ... The study showed CT perfusion had,100 percent accuracy for detecting the ...
... of America, Inc.,(OTC Bulletin Board: CPCF), a company ... in endovascular procedures, today announced,that it is implementing ... its MedClose(TM) investigational-stage medical device. In,the roll out ... Medical,Product Service GmbH (MPS) of Germany to act ...
... Emergency Room Life Through Eyes of Poet Doctor, ... care,crisis in America to the natural fear of illness ... wonder and poetry in medical practice.,Bertrand P. Fote has ... his,work as an emergency physician, and he captures this ...
Cached Medicine News:Health News:Celebrity Cosmetic Dentist to Guest Co-Host New National Day Time Talk Show 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 2Health News:West VA University Study Calls for New Method of Stroke Diagnosis 3Health News:West VA University Study Calls for New Method of Stroke Diagnosis 4Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 2Health News:CPC Appoints Medical Product Service GmbH as Authorized European Representative for MedClose(TM) System 3Health News:Physician Portrays Powerful Poetry at Heart of Human Condition 2
Trans-Blot Plus Gel/Cassette Assembly Tray...
Ice block will provide sufficient cooling for most normal blotting applications. Sealed block is held submerged in transfer buffer. Ice block will not spill during refreezing....
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Advantages of using the Antigen-Antibody Pens-Using a ... and developed specialized fountain pens, called Antigen-Antibody ... or write/mark the blotting membranes in any ... formulated antigen-bonded colored dyes helps to see ...
Medicine Products: